MEIRAGTX HOLDINGS PLC(NASDAQ:MGTX) stock News

MGTX Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Zacks Investment Research - Mentions: CLNN

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: XLO

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

2 months ago - By: The Motley Fool

MeiraGTx Sales Jump 1,133 Percent

2 months ago - By: MeiraGTx

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

2 months ago - By: MeiraGTx

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

2 months ago - By: Zacks Investment Research - Mentions: IFRX

InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates

5 months ago - By: Benzinga - Mentions: CAMT COIN DAC PVH ...

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday

5 months ago - By: MeiraGTx

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

5 months ago - By: MeiraGTx

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

5 months ago - By: Zacks Investment Research - Mentions: AFMD

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

5 months ago - By: MeiraGTx

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

5 months ago - By: MeiraGTx

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

5 months ago - By: MeiraGTx

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

5 months ago - By: MeiraGTx

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

7 months ago - By: Benzinga - Mentions: RGC PHAR PSTV HEPA ...

12 Health Care Stocks Moving In Thursday's Intraday Session

7 months ago - By: MeiraGTx

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

7 months ago - By: MeiraGTx

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

7 months ago - By: MeiraGTx

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

7 months ago - By: MeiraGTx

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

7 months ago - By: MeiraGTx

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

7 months ago - By: MeiraGTx

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

8 months ago - By: MeiraGTx

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

8 months ago - By: MeiraGTx

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

10 months ago - By: MeiraGTx

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

10 months ago - By: MeiraGTx

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

11 months ago - By: MeiraGTx

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

11 months ago - By: MeiraGTx

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

a year ago - By: MeiraGTx

MEIRAGTX HOLDINGS PLC (MGTX) Stock News

MGTX Latest News, Press Relases and Analysis

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

MeiraGTx Sales Jump 1,133 Percent

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

12 Health Care Stocks Moving In Thursday's Intraday Session

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress